TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 0.400nMAssay Description:Inhibition of recombinant SAE (unknown origin) assessed as reduction in transfer of SUMO1 to UBC9 using SUMO1 as a substrate in presence of ATP at Km...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of SAE in human HCT116 cells assessed as reduction in redistribution of SUMO2/3 proteins from nucleus to cytosol incubated for 4 hrs by im...More data for this Ligand-Target Pair
TargetSUMO-activating enzyme subunit 1/2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 3nMAssay Description:Inhibition of SAE in human HCT116 cells assessed as reduction in redistribution of SUMO2/3 proteins from nucleus to cytosol incubated for 4 hrs by im...More data for this Ligand-Target Pair
TargetCarbonic anhydrase 2(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 10nMAssay Description:Inhibition of recombinant human CA2 expressed in Escherichia coli using fluorescein diacetate as substrate at pH 3.5 by fluorometric esterase assayMore data for this Ligand-Target Pair
TargetCarbonic anhydrase 1(Homo sapiens (Human))
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 50nMAssay Description:Inhibition of human erythrocyte CA1 using fluorescein diacetate as substrate at pH 3.5 by fluorometric esterase assayMore data for this Ligand-Target Pair
TargetNEDD8-activating enzyme E1 catalytic subunit(Homo sapiens)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 386nMAssay Description:Inhibition of recombinant NAE (unknown origin) in presence of ATP at Km concentration by HTRF assayMore data for this Ligand-Target Pair
TargetNEDD8-activating enzyme E1 catalytic subunit(Homo sapiens)
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Millennium Pharmaceuticals, A Wholly Owned Subsidiary Of Takeda Pharmaceuticals
Curated by ChEMBL
Affinity DataIC50: 386nMAssay Description:Inhibition of recombinant NAE (unknown origin) in presence of ATP at Km concentration by HTRF assayMore data for this Ligand-Target Pair